Propanc Biopharma Completes $4 Million Public Offering to Advance Cancer Stem Cell Therapy Development

Propanc Biopharma, Inc. (NASDAQ: PPCB) has completed an underwritten public offering of 1,000,000 shares of common stock at $4.00 per share, generating $4 million in gross proceeds before deducting underwriting discounts and expenses. The offering, which closed on August 18, 2025, represents a significant capital infusion for the clinical-stage biopharmaceutical company. The shares commenced trading on the Nasdaq Capital Market on August 15, 2025, with D. Boral Capital LLC and Craft Capital Management LLC serving as book running managers for the transaction.

The company also granted the underwriter a 45-day option to purchase up to 150,000 additional shares, providing potential for additional funding. This capital raise comes at a critical juncture for Propanc Biopharma as it advances its innovative approach to cancer treatment. The company is developing a novel therapy that utilizes pancreatic proenzymes to target and eradicate cancer stem cells, specifically focusing on preventing recurrence and metastasis in patients suffering from pancreatic, ovarian, and colorectal cancers.

The scientific foundation of Propanc's therapy is based on the understanding that enzymes stimulate biological reactions in the body, with pancreatic enzymes potentially representing the body's primary defense against cancer. This offering provides essential funding to advance the clinical development of what could represent a paradigm shift in cancer treatment. For more information about the company's research and development efforts, visit https://www.propanc.com.

The successful completion of this $4 million offering demonstrates investor confidence in Propanc's scientific approach and development strategy. The funding will enable the company to accelerate its clinical programs and advance its proenzyme therapy through necessary regulatory milestones. The focus on cancer stem cells addresses a significant unmet medical need, as these cells are often responsible for treatment resistance and disease recurrence in solid tumors.

This capital raise occurs within the broader biotechnology investment landscape, where companies developing innovative cancer therapies continue to attract significant investor interest. The additional funding positions Propanc Biopharma to make substantial progress in its mission to develop effective treatments for some of the most challenging cancers. The company's approach, targeting the root cause of cancer recurrence and metastasis, represents an important direction in oncology research and drug development.